
Perrigo Company plc
NYSE•PRGO
CEO: Mr. Patrick Lockwood-Taylor
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1991-12-17
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Contact Information
Market Cap
$1.77B
P/E (TTM)
-34.3
81.2
Dividend Yield
9.0%
52W High
$30.93
52W Low
$12.17
52W Range
Rank48Top 50.7%
3.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$1.04B-4.06%
4-Quarter Trend
EPS
$0.05-133.33%
4-Quarter Trend
FCF
$29.80M+97.35%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Operating Income Rebounds Strongly Nine months operating income reached $164.9M, reversing prior year's $1.3M loss; Gross margin improved 20 basis points to 36.0%.
CSCA/CSCI Segment Profitability CSCA operating income $203.7M; CSCI operating income $136.2M, showing strong profit flow-through across segments.
Cash Flow from Operations Operating cash flow increased $12.8M to $63.1M for nine months, driven by improved net loss position and adjustments.
Tax Law Benefit Realized OBBBA enactment estimated to provide $28.0M tax benefit for 2025, improving realizability of deferred tax assets.
Risk Factors
Divestiture/Impairment Charges Recorded $1.2M goodwill impairment for Richard Bittner sale; Dermacosmetics assets held for sale as of September 2025.
Macroeconomic Volatility Risks Ongoing uncertainty from tariffs, geopolitical conflicts, and inflation may increase COGS by $10M-$20M in Q4 2025.
Ongoing Price-Fixing Litigation Price-fixing lawsuits remain active; court opinion issued but final judgment pending resolution of potential adverse impacts.
Infant Formula Remediation Costs Remediation costs for Wisconsin facility reached approximately $22.6M cash costs, impacting output and market share recovery.
Outlook
Project Energize Savings Expected Project Energize targets $140M to $170M pre-tax savings by end of 2026, with substantial costs incurred by end of 2025.
Strategic Review of Infant Formula Strategic review announced for infant formula business in November 2025, assessing alternatives and optimizing portfolio focus.
Supply Chain Reinvention Progress Supply Chain Reinvention aims for $200M to $300M run-rate savings by 2028; $150M to $200M expected by end of 2025.
Dermacosmetics Sale Expected Dermacosmetics Business sale expected to close in the first quarter of 2026, subject to regulatory approvals.
Peer Comparison
Revenue (TTM)
PRGO$4.28B
AMRX$2.93B
ICUI$2.32B
Gross Margin (Latest Quarter)
TARS93.0%
90.1%
INDV73.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| INDV | $4.40B | 26.5 | -60.4% | 3.7% |
| AMRX | $3.92B | 663.7 | 5.1% | 74.6% |
| ICUI | $3.65B | -627.9 | -0.3% | 32.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.9%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 26, 2026
EPS:$0.81
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 27, 2025|Filed: Nov 5, 2025|Revenue: $1.04B-4.1%|EPS: $0.05-133.3%MissForm 10-Q - Q2 2025
Period End: Jun 28, 2025|Filed: Aug 6, 2025|Revenue: $1.06B-0.9%|EPS: $-0.06-92.1%MissForm 10-Q - Q1 2025
Period End: Mar 29, 2025|Filed: May 7, 2025|Revenue: $1.04B-3.5%|EPS: $-0.05-600.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $4.37B-6.1%|EPS: $-1.25-1231.2%MissForm 10-Q - Q3 2024
Period End: Sep 28, 2024|Filed: Nov 6, 2024|Revenue: $1.09B-3.2%|EPS: $-0.15-236.4%MissForm 10-Q - Q2 2024
Period End: Jun 29, 2024|Filed: Aug 2, 2024|Revenue: $1.07B-10.7%|EPS: $-0.77-1270.2%MissForm 10-Q - Q1 2024
Period End: Mar 30, 2024|Filed: May 7, 2024|Revenue: $1.08B-8.4%|EPS: $0.01-222.0%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 27, 2024|Revenue: $4.66B+4.6%|EPS: $-0.09+90.3%Miss